SAGE Therapeutics (SAGE) Misses Q2 EPS by 22c
Tweet
Share
E-mailGet Alerts SAGE Hot Sheet
Join SI Premium – FREE
SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($0.90), $0.22 worse than the analyst estimate of ($0.68).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
- FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer
- Delta Air Lines stock climbs on earnings beat and strong guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
